Annals of the Rheumatic Diseases (ARD) is published by the BMJ Publishing Group Ltd and the European League Against Rheumatism (EULAR) and is an international peer review journal committed to promoting the highest standards of scientific exchange and education.

ARD covers all aspects of rheumatology, which includes the spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders. ARD publishes basic, clinical, and translational scientific research. Concise scientific communication is encouraged and peer reviewed proceedings of international meetings are featured. Educational papers include state of the art reviews, "how to" articles and educational cases that focus on problems faced in clinical practice. The journal was first published in 1939 and has an authorative global Editorial Board, and a growing international readership.

ARD is the official journal of EULAR - the European League Against Rheumatism and all (scientific) delegates to the annual EULAR congress receive a complimentary 12 month subscription to the journal.

Annals of the Rheumatic Diseases seeks to publish significant advances in scientific understanding which are likely to impact on clinical practice within the medium term. Articles illustrating basic mechanisms and their application to clinical material will be welcomed. We aim to cover all areas of Rheumatology and through a system of commentaries and to make clear the relevance of scientific advances to clinical practice. The priorities are originality and excellence. We aim to ensure a fair and independent peer review system and to publish articles which follow the highest ethical standards concerning research conduct.

Please click here to view the Impact Factor.

1. Median time from submission to first decision = 7 weeks
   1. 15% of papers rejected without external peer review within 1 week
2. Time from acceptance to publication = 4 months
   1. Full original articles published Online First within 2 weeks